Loading…
Loading…
I guess beyond biotech performance, I mean, is there anything else that's sort of getting worse?
how sustainable do you think these levels of growth are going forward? I mean, do they face easy comps year-over-year?
Was there any catch-up in fiscal Q1 from some of those disruptions you saw at the end of the last fiscal year?
next quarter, assuming the same level of growth, minus 1%, what does that sort of imply for the EBIT margin
how does pharma sort of fit within that framework?
Could you quantify how much maybe pull forward you saw in the fiscal fourth quarter?